Login to Your Account



Algeta's Series A Gets EUR23M For Alpha-Emitting Isotope

By Cormac Sheridan


Wednesday, September 7, 2005
Algeta ASA raised €23 million (US$28.8 million) in a Series A funding to continue development of its lead product, Alpharadin, a cancer therapeutic based on radium-223 (Ra-223), which is undergoing Phase II studies in skeletal metastases arising from prostate cancer. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription